The development of proteasome inhibitors as anticancer drugs

Cancer Cell

Volumn 5, Issue 5, 2004, Pages 417-421

  Adams, Julian ^a  

^a Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB;

APOPTOSIS; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL TRIAL; DRUG DESIGN; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; METASTASIS INHIBITION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION;

EID: 2342667387     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00120-5     Document Type: Review

References (52)

1. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 7:2002;9-16. a
2. Adams J. Proteasome inhibition. A novel approach to cancer therapy Trends Mol. Med. 8(suppl 4):2002;S49-S54. b
3. Adams J. The proteasome. Structure, function, and role in the cell Cancer Treat. Rev. 29(suppl 1):2003;3-9
4. Adams J. The proteasome. A suitable antineoplastic target Nat. Rev. Cancer. 4:2004;349-360
5. Adams J., Behnke M., Chen S., Cruickshank A.A., Dick L.R., Grenier L., Klunder J.M., Ma Y.-T., Plamondon L., Stein R.L. Potent and selective inhibitors of the proteasome. Dipeptidyl boronic acids Bioorg. Med. Chem. Lett. 8:1998;333-338
6. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., Elliot P.J. Proteasome inhibitors a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622
7. Adams J., Palombella V.J., Elliott P.J. Proteasome inhibition. A new strategy in cancer treatment Invest. New Drugs. 18:2000;109-121
8. Aghajanian C., Soignet S., Dizon D.S., Pien C.S., Adams J., Elliott P.J., Sabbatini P., Miller V., Hensley M.L., Pezzulli S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8:2002;2505-2511
9. Albanell J., Baselga J., Guix M., Twelves C.J., Glasspool R., Awada A., Dodion P., Esseltine D., Werner M.C., Piccart M., et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;16
10. Almond J.B., Cohen G.M. The proteasome. A novel target for cancer chemotherapy Leukemia. 16:2002;433-443
11. An B., Goldfarb R.H., Siman R., Dou Q.P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5:1998;1062-1075
12. Appleman L.F., Ryan D.P., Clark J.W., Eder J.P., Fishman M., Cusack J.C., Fidias P., Supko J.G., Esseltine D., Kashala O. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 22:2003;209
13. Bladé J., Samson D., Reece D., Apperley J., Bjorkstrand B., Gahrton G., Gertz M., Giralt S., Jagannath S., Vesole D. for the Myeloma Subcommittee of the European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br. J. Haematol. 102:1998;1115-1123
14. Bold R.J., Virudachalam S., McConkey D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100:2001;11-17
15. Cusack J.C. Jr., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J., Baldwin S.S. Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341. Implications for systemic nuclear factor-κB inhibition Cancer Res. 61:2001;3535-3540
16. Desai S.D., Li T.K., Rodriguez-Bauman A., Rubin E.H., Liu L.F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 61:2001;5926-5932
17. Drexler H.C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA. 94:1997;855-860
18. Drexler H.C.A., Risau W., Konerding M.A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 14:2000;65-77
19. Frankel A., Man S., Elliott P., Adams J., Kerbel R.S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6:2000;3719-3728
20. Goy A., Hart S., Pro B., McLaughlin P., Younes A., Dang N., Fayad L., Romaguera J., Cabanillas F., Hagemeister F., et al. Report of a phase II study of proteasome inhibitor bortezomib (VELCADE™) in patients with relapsed or refractory indolent or aggressive lymphomas. Blood. 102:2003;180a
21. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., Jordan C.T. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA. 99:2002;16220-16225
22. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:2001;3071-3076
23. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., Munshi N., Dang L., Castro A., Palombella V., et al. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277:2002;16639-16647
24. Karin M., Cao Y., Greten F.R., Li Z.W. NF-κB in cancer. From innocent bystander to major culprit Nat. Rev. Cancer. 2:2002;301-310
25. Kettner C.A., Shenvi A.B. Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. J. Biol. Chem. 259:1984;15106-15114
26. King R.W., Deshaies R.J., Peters J.-M., Kirschner M.W. How proteolysis drives the cell cycle. Science. 274:1996;1652-1659
27. Kisselev A.F., Goldberg A.L. Proteasome inhibitors. From research tools to drug candidates Chem. Biol. 8:2001;739-758
28. LeBlanc R., Catley L.P., Hideshima T., Lentzsch S., Mitsiades C.S., Mitsiades N., Neuberg D., Goloubeva O., Pien C.S., Adams J., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:2002;4996-5000
29. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA. 100:2003;9946-9951
30. Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway. Involvement in tumor survival and progression Proc. Natl. Acad. Sci. USA. 97:2000;3850-3855
31. Ling Y.H., Liebes L., Jiang J.D., Holland J.F., Elliott P.J., Adams J., Muggia F.M., Perez-Soler R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 9:2003;1145-1154
32. Ma M.H., Yang H.H., Parker K., Manyak S., Friedman J.M., Altamirano C., Wu Z.Q., Borad M.J., Frantzen M., Roussos E., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9:2003;1136-1144
33. MacLaren A.P., Chapman R.S., Wyllie A.H., Watson C.J. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 8:2001;210-218
34. Masdehors P., Merle-Béral H., Maloum K., Omura S., Magdelénat H., Delic J. Deregulation of the ubiquitin system an dp53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 96:2000;269-274
35. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.-T., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents. therapeutic applications Blood. 101:2003;2377-2380
36. Nussbaum A.K., Dick T.P., Keilholz W., Schirle M., Stevanovic S., Dietz K., Heinemeyer W., Groll M., Wolf D.H., Huber R., et al. Cleavage motifs of the yeast 20S protease beta subunits deduced from digests of enolase 1. Proc. Natl. Acad. Sci. USA. 95:1998;12504-12509
37. O'Connor O., Wright J., Moskowitz C.H., Muzzy J., MacGregor-Cortelli B., Hamlin P., Straus D., Trehu E., Schenkein D.P., Zelenetz A.D. Promising activity of the proteasome inhibitor bortezomib (VELCADE™) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Blood. 102:2003;636a
38. Ogiso Y., Tomida A., Lei S., Omura S., Tsuro T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 60:2000;2429-2434
39. Orlowski R.Z., Eswara J.R., Lafond-Walker A., Grever M.R., Orlowski M., Dang C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58:1998;4342-4348
40. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., Adams J., Esseltine D.L., Elliott P.J., Pien C.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20:2002;4420-4427
41. Pajonk F., Pajonk K., McBride W.H. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;1025-1032
42. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., Ford R.J. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 171:2003;88-95
43. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2003;2609-2617
44. Russo S.M., Tepper J.E., Baldwin A.S. Jr., Liu R., Adams J., Elliott P., Cusack J.C. Jr. Enhancement of radiosensitivity by proteasome inhibition. implications for a role of NF-κB Int. J. Radiat. Oncol. Biol. Phys. 50:2001;183-193
45. Shah S.A., Potter M.W., McDade T.P., Ricciardi R., Perugini R.A., Elliott P.J., Adams J., Callery M.P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 82:2001;110-122
46. Sunwoo J.B., Chen Z., Dong G., Yeh N., Bancroft C.C., Sausville E., Adams J., Elliott P., Van Waes C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7:2001;1419-1428
47. Tan C., Waldmann T.A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 62:2002;1083-1086
48. Teicher B.A., Ara G., Herbst R., Palombella V.J., Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5:1999;2638-2645
49. Wang C.Y., Cusack J.C. Jr., Liu R., Baldwin A.S. Jr. Control of inducible chemoresistance. Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kB Nat. Med. 5:1999;412-417
50. Weber P.C., Lee S.L., Lewandowski F.A., Schadt M.C., Chang C.W., Kettner C.A. Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro- boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs. Biochemistry. 34:1995;3750-3757
51. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 2:2003;835-843
52. Zhang H.G., Wang J., Yang X., Hsu H.C., Mountz J.D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 23:2004;2009-2015